Literature DB >> 10901382

Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).

T D Bradshaw1, M S Chua, S Orr, C S Matthews, M F Stevens.   

Abstract

2-(4-aminophenyl)benzothiazole (CJM 126) elicits potent growth inhibition in human-derived breast carcinoma cell lines, including oestrogen receptor-positive (ER+) MCF-7wt cells. Analogues substituted in the 3' position with I (DF 129), CH3 (DF 203), or Cl (DF 229) possess an extended profile of antitumour activity with remarkable selective activity in cell lines derived from solid tumours associated with poor prognosis, e.g. breast, ovarian, renal and colon. Growth inhibition occurs via unknown, possibly novel mechanism(s) of action. Two cell lines have been derived from sensitive MCF-7wt breast cancer cells (IC50 value < 0.001 microM) following long-term exposure to 10 nM or 10 microM CJM 126, MCF-7(10 nM 126) and MCF-7(10 microM 126) respectively, which demonstrate acquired resistance to this agent (IC50 > 30 microM) and cross-resistance to DF 129, DF 203 and DF 229. Sensitivity to tamoxifen, benzo[a]pyrene (BP), mitomyin C, doxorubicin and actinomycin D is retained. Resistance may, in part, be conferred by the constitutively increased expression of bcl-2 and p53 proteins detected in MCF-7(10 nM 126) and MCF-7(10 microM 126 lysates. Significantly decreased depletion of CJM 126 (30 microM) from nutrient medium of MCF-7(10 microM 126) cells was observed with predominantly cytoplasmic drug localization and negligible DNA strand breaks. N-acetyl transferase (NAT)1 and NAT2 proteins were expressed by all three MCF-7 sub-lines, but significantly higher expression of NAT2 was accompanied by enhanced acetylation efficacy in MCF-7(10 nM 126) cells. In contrast, CJM 126 (30 microM) was rapidly depleted from nutrient medium of MCF-7(10 microM 126) culture and accessed nuclei of these cells exerting damage to DNA. The major biotransformation product of CJM 126 in MCF-7(10 microM 126) cells was 2-(4-aminophenyl)-6-hydroxybenzothiazole (6-OH 126). This metabolite possessed no antitumour activity. Accordingly, in this sub-line, low constitutive expression and activity of cytochrome P450 (CYP) 1A1 was detected.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901382      PMCID: PMC2363474          DOI: 10.1054/bjoc.2000.1231

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

Review 1.  Molecular mechanisms of drug resistance.

Authors:  J D Hayes; C R Wolf
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo.

Authors:  D F Shi; T D Bradshaw; S Wrigley; C J McCall; P Lelieveld; I Fichtner; M F Stevens
Journal:  J Med Chem       Date:  1996-08-16       Impact factor: 7.446

3.  Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole.

Authors:  A Pastrakuljic; B K Tang; E A Roberts; W Kalow
Journal:  Biochem Pharmacol       Date:  1997-02-21       Impact factor: 5.858

4.  Cell-specific regulation of human CYP1A1 and CYP1B1 genes.

Authors:  S Kress; W F Greenlee
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

5.  Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.

Authors:  S A Akman; G Forrest; F F Chu; R S Esworthy; J H Doroshow
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

6.  Cancer therapy meets p53.

Authors:  K W Kinzler; B Vogelstein
Journal:  N Engl J Med       Date:  1994-07-07       Impact factor: 91.245

7.  An information-intensive approach to the molecular pharmacology of cancer.

Authors:  J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; J K Buolamwini; W W van Osdol; A P Monks; D A Scudiero; E A Sausville; D W Zaharevitz; B Bunow; V N Viswanadhan; G S Johnson; R E Wittes; K D Paull
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

8.  N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland.

Authors:  N Sadrieh; C D Davis; E G Snyderwine
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

Review 9.  Metabolic activation of toxins: tissue-specific expression and metabolism in target organs.

Authors:  O Pelkonen; H Raunio
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

10.  p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs.

Authors:  R D Malcomson; M Oren; A H Wyllie; D J Harrison
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more
  4 in total

1.  DNA Binding, Cleavage and Antibacterial Activity of Mononuclear Cu(II), Ni(II) and Co(II) Complexes Derived from Novel Benzothiazole Schiff Bases.

Authors:  Narendrula Vamsikrishna; Marri Pradeep Kumar; Somapangu Tejaswi; Aveli Rambabu
Journal:  J Fluoresc       Date:  2016-05-11       Impact factor: 2.217

2.  Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.

Authors:  Ragu Kanagasabai; Karthikeyan Krishnamurthy; Lawrence J Druhan; Govindasamy Ilangovan
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

3.  Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.

Authors:  C-O Leong; M Gaskell; E A Martin; R T Heydon; P B Farmer; M C Bibby; P A Cooper; J A Double; T D Bradshaw; M F G Stevens
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

4.  Retrospective analysis of estrogen receptor 1 and N‑acetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines.

Authors:  Samantha M Carlisle; David W Hein
Journal:  Int J Oncol       Date:  2018-06-11       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.